Drug Trial Radar · NCT05629741
A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101
Last checked: Nov 19, 2026Latest source record: Oct 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
28
Actual
Start
Nov 14, 2022
Primary completion
Aug 2, 2024
Study completion Aug 2, 2024
Sponsor
- Lead sponsor
- Clarametyx Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
CMTX-101 is a bacterial biofilm disrupting monoclonal antibody being developed as an adjunct therapy with standard of care antibiotics. The goal of this clinical trial is to assess the safety and tolerability of CMTX-101 in healthy volunteers followed by a similar assessment in patients with suspected or confirmed community acquired bacterial pneumonia of moderate severity. The main questions the study aims to answer are: * Are single ascending doses of a CMTX-101 intravenous (IV) infusion safe and tolerated * What is the pharmacokinetic (PK) profile of single-ascending doses CMTX 101 * Do single ascending doses of CMTX 101 induce development of anti-drug antibodies (ADA) and neutralizing antibodies (Nabs) Exploratory efficacy biomarkers will also be measured in the patient part of the study. Participants will be administered a single IV infusion of CMTX-101 over a 60-minute period; patients will receive the infusion after starting standard of care antibiotics.
Conditions
- Community-acquired Pneumonia
- Bacterial Pneumonia
Interventions
CMTX-101Drug
Administered as specified in the treatment arm
PlaceboDrug
Administered as specified in the treatment arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and % of healthy subjects experiencing Adverse Events following ascending doses of a single CMTX-101 IV infusionTime frame: Cohorts 1 and 2: Day 1 to Day 29. Cohorts 3 and 4: Day 1 to Day 100.
- Number and % of healthy subjects experiencing Serious Adverse Events following ascending doses of a single CMTX-101 IV infusionTime frame: Cohorts 1 and 2: Day 1 to Day 29. Cohorts 3 and 4: Day 1 to Day 100.
- Number and % of healthy subjects experiencing Solicited Adverse Events following ascending doses of a single CMTX-101 IV infusionTime frame: Cohorts 1 and 2: Day 1 to Day 29. Cohorts 3 and 4: Day 1 to Day 100.
- Number and % of hospitalized subjects with suspected or confirmed CABP of moderate severity experiencing Adverse Events following dosing of a single CMTX-101 IV infusionTime frame: Day 1 to Day 35
- Number and % of hospitalized subjects with suspected or confirmed CABP of moderate severity experiencing Serious Adverse Events following dosing of a single CMTX-101 IV infusionTime frame: Day 1 to Day 35
- Number and % of hospitalized subjects with suspected or confirmed CABP of moderate severity experiencing Solicited Adverse Events following dosing of a single CMTX-101 IV infusionTime frame: Day 1 to Day 35
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Augusta University Health
Augusta, Georgia
Snake River Research, PLLC
Idaho Falls, Idaho
University of Louisville
Louisville, Kentucky
Wayne State University
Detroit, Michigan
Buffalo VA Medical Center
Buffalo, New York
Medpace Clinical Pharmacology Unit
Cincinnati, Ohio
The Ohio State University
Columbus, Ohio
University of Virginia School of Medicine
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.